About
Our Focus
Our Leadership
Board of Directors
Scientific Advisors
Our Science
Our Approach
Pipeline Overview
AUM001
AUM601
AUM302
AUM003
Publications and Posters
Clinical Trials
Investors
Overview
Press Release
News Media
Events
Investor Kit
Career
Publications and Posters
AUM001
AUM601
AUM302
AUM003
AUM001
Publications:
The structure and kinetics of the novel selective inhibitor ETC-206 used against Blast Crisis Chronic Myeloid Leukemia
The role of eIF4E in the tumour progression of blast crisis chronic myeloid leukemia
Novel Mnk Inhibitors activities and interactions modelled using computational approaches
The interactions between inhibitors and Mnk kinases determining a key role in their stability and potency
AUM601
Publications:
A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies (2021)
602TiP – A first-in-human study of NOV1601 (CHC2014), small-molecule inhibitor of TRK family proteins, in adult patients with solid organ malignancies (2020)
pan-TRK inhibitor NOV1601
AUM302
Publications :
Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. (2021)
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer (2020)
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma (2020)
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.(2020)
Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models (2018)
Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC (2017)
Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma (2016)
Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL) (2015)
Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma (2014)
Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors (2013)
AUM003
Publications:
MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma.(2021)
Topography of transcriptionally active chromatin in glioblastoma (2021)
Rescue of oxytocin response and social behaviour in a mouse model of autism (2020)